Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress chronic and sustained inflammation — will now be exclusively marketed by Dr. Reddy’s Laboratories in the U.S., Canada, and the U.K., as well as in the European Union, should…
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the oral therapy for six months led to “meaningful slowing of disease progression” in people with amyotrophic lateral sclerosis (ALS), the company said in a press release announcing top-line…
Anxiety is common among people newly diagnosed with amyotrophic lateral sclerosis (ALS) and their family members, a small study from Sweden reports. However, symptoms of anxiety tended to ease about six or so months later for patients, while they continued to affect relatives, many who are caregivers, two years…
A particular genetic variant that boosts the activity of the NEAT1 gene can push the onset of amyotrophic lateral sclerosis (ALS) forward by more than three years, according to data from a large patient group in China. While the exact function of NEAT1 in ALS needs to be explored,…
Rapamycin, an approved medication used to prevent organ rejection after a kidney transplant, didn’t increase the number of regulatory T-cells in adults with amyotrophic lateral sclerosis (ALS) who are taking part in a Phase 2 clinical trial. Along with not meeting its primary goal, RAP-ALS (NCT03359538) also…
Spinogenix has won a nearly $1 million grant from the U.S. Department of Defense (DoD) to move ahead with clinical testing of SPG302, a small molecule candidate for amyotrophic lateral sclerosis (ALS). This is DoD’s Congressionally Directed Medical Research Programs’ second grant to the company, following a…
A first healthy volunteer has been dosed in a Phase 1 clinical study evaluating how safe and well tolerated is CVN293, a treatment candidate for amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, the therapy’s developer, Cerevance, announced. The treatment, given orally, is designed to block a protein…
Note: This story was updated Sept. 25, 2023, to correct that TW001 uses the same active ingredient as Radicava and Radicava ORS but is a different therapy. Treeway has chosen Specialised Therapeutics Asia, known as ST, as its partner to market TW001, an oral formulation of edaravone, for…
While eating a high-calorie diet is safe and well tolerated, it does not appear to slow disease progression or reduce the risk of death in people with amyotrophic lateral sclerosis (ALS), a review of published clinical trials found. Combining data from multiple trials helps to create a single, more…
A “velcro-like” protein called alpha-5 integrin consistently is found at high levels in immune cells near motor neurons being damaged or killed in people with amyotrophic lateral sclerosis (ALS) and those of mice in a disease model, a study reports. Blocking the protein in the mice slowed disease progression,…
Get regular updates to your inbox.
